INDIANAPOLIS, Indiana, June 7, 2026
Eli Lilly and Company has announced new data demonstrating that Foundayo® (orforglipron), the only oral GLP-1 receptor agonist that can be taken without food or water restrictions, delivered significant weight loss in women across every stage of menopause. Presented at the American Diabetes Association (ADA) 2026 Scientific Sessions, the findings are based on post-hoc analyses involving more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 clinical trials. The results provide important new insights into obesity treatment during menopause, a life stage frequently associated with hormonal changes, increased abdominal fat accumulation, and greater difficulty achieving sustained weight loss. The data reinforce the growing role of oral GLP-1 therapies in addressing obesity and cardiometabolic health challenges among women facing menopause-related weight gain.
Significant Weight Reduction Observed Across All Menopause Stages
The analyses revealed that women taking the highest dose of Foundayo 17.2 mg achieved clinically meaningful weight loss regardless of whether they were pre-menopausal, perimenopausal, or post-menopausal. In the ATTAIN-1 trial, which enrolled adults with obesity or overweight without diabetes, women in perimenopause experienced the greatest reductions, losing up to 30.4 pounds (14.4%), while post-menopausal women lost up to 28.2 pounds (14.1%) and pre-menopausal women lost up to 28.0 pounds (12.8%) over 72 weeks. The results are particularly notable because menopause is often linked to biological changes that make weight management increasingly challenging.
Researchers emphasized that obesity treatment efficacy has historically not been extensively evaluated according to menopausal status, making these findings an important contribution to understanding how modern weight-loss therapies perform in women at different hormonal stages. In addition to body weight reductions, a substantial proportion of participants achieved clinically meaningful milestones, including weight reductions of 15% or greater, a benchmark associated with significant metabolic and cardiovascular benefits.
Positive Outcomes Extend to Women Living With Type 2 Diabetes
Advertisement
The benefits of Foundayo were also evident among women living with obesity or overweight alongside type 2 diabetes. In the ATTAIN-2 Phase 3 trial, participants achieved significant weight reductions despite the additional challenges commonly associated with diabetes management. Women who were post-menopausal lost up to 27.8 pounds (13.6%), while pre-menopausal participants lost up to 23.4 pounds (11.3%) and perimenopausal participants lost up to 18.5 pounds (8.9%). Importantly, the therapy demonstrated consistent efficacy across all menopausal stages, reinforcing its potential applicability to a broad patient population.
Researchers noted that the ability to achieve substantial weight loss in patients with type 2 diabetes is particularly meaningful because diabetes can often complicate weight management efforts. The findings further support the expanding role of GLP-1 receptor agonists in addressing both obesity and metabolic disease while providing clinicians with additional evidence regarding treatment effectiveness in women experiencing hormonal transitions.
Oral GLP-1 Innovation Supports Cardiometabolic Health
Beyond body weight reduction, women receiving Foundayo experienced meaningful decreases in waist circumference, a key indicator associated with abdominal fat and cardiometabolic risk. Participants in ATTAIN-1 recorded waist circumference reductions of up to 4.9 inches (12.5 cm), while women in ATTAIN-2 achieved reductions of up to 4.3 inches (11.0 cm). These improvements suggest potential benefits extending beyond weight loss alone and highlight the therapy’s broader impact on metabolic health. Foundayo is distinguished as a once-daily oral GLP-1 receptor agonist that can be taken at any time without food or water restrictions, offering patients a convenient alternative to injectable therapies.
As obesity continues to affect millions of women worldwide and menopause-related weight gain remains a significant healthcare challenge, the ADA 2026 findings strengthen the evidence supporting Foundayo as a promising treatment option capable of delivering substantial weight loss, reduced abdominal adiposity, and improved long-term health outcomes across diverse female populations.
Source: Eli Lilly press release
